The SPORE Career Development Program (CDP) will prepare physicians and scientists for independent careers in translational research in thyroid cancer. Our goal is that the investigators funded through this process will spend their professional lifetimes conducting translational research in thyroid cancer, and become intellectual leaders in the field. Memorial Sloan-Kettering Cancer Center (MSKCC) is ideally suited for this task, because of the scientific and clinical environment at our main campus and affiliated institutions, and our long tradition of training physicians and scientists of the highest quality. Our institutional environment includes numerous NIH training grants, including a K12 for translational science training, a T32 grant to train PhDs in translational research in oncology, a Certificate Program in Clinical Investigation integrated with the Clinical and Translational Science Program at Weill Cornell, and a well established junior faculty mentoring program. We plan to use the SPORE Career Development funds over the next 5 years to enhance the existing formal training programs and tap into the talent of students matriculating and graduating from the Gerstner Sloan-Kettering Graduate School for Biomedical Sciences. We will encourage more physician trainees to focus on translational research in thyroid cancer and strive to attract basic scientists who are interested in devoting their postdoctoral training to making discoveries that have a realistic potential to lead to clinical applications.
The specific aims of the MSKCC Thyroid SPORE Career Development Program are to: 1) To support the education, training and research of advanced postdoctoral fellows for careers in translational research in thyroid cancer, using a dual clinical and laboratory mentorship model.
This aim, integrated but not directly funded by the SPORE, will lead to candidates for aim 2. 2) To recruit and mentor junior faculty to work in translational research in thyroid cancer. A Career Development Committee, cochaired by Dr. James Fagin and Dr. David Pfister, will direct the Career Development Program. The Committee will include representatives from both clinical and basic sciences.

Public Health Relevance

Thyroid cancer has grown significantly in incidence over the last 30 years, and is a highly prevalent disease. Thyroid cancer presents a spectrum of challenges, from overtreatment of patients with a highly favorable prognosis to lack of effective therapies for patients with metastatic radioiodine-refractory disease and anaplastic cancers. CDP will play a key role in recruiting and training clinicians and scientists to develop as translational research investigators in thyroid cancer, with the goal of improving the outcomes of the disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA172012-01A1
Application #
8738877
Study Section
Special Emphasis Panel (ZCA1-RPRB-0 (M1))
Project Start
2014-09-19
Project End
2019-08-31
Budget Start
2014-09-19
Budget End
2015-08-31
Support Year
1
Fiscal Year
2014
Total Cost
$63,620
Indirect Cost
$23,053
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Ganly, Ian; Makarov, Vladimir; Deraje, Shyamprasad et al. (2018) Integrated Genomic Analysis of Hürthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes. Cancer Cell 34:256-270.e5
De Martino, Daniela; Yilmaz, Emrullah; Orlacchio, Arturo et al. (2018) PI3K blockage synergizes with PLK1 inhibition preventing endoreduplication and enhancing apoptosis in anaplastic thyroid cancer. Cancer Lett 439:56-65
Marlow, Laura A; Rohl, Stephen D; Miller, James L et al. (2018) Methodology, Criteria, and Characterization of Patient-Matched Thyroid Cell Lines and Patient-Derived Tumor Xenografts. J Clin Endocrinol Metab 103:3169-3182
Krishnamoorthy, Gnana P; Davidson, Natalie R; Leach, Steven D et al. (2018) EIF1AX and RAS mutations cooperate to drive thyroid tumorigenesis through ATF4 and c-MYC. Cancer Discov :
Untch, Brian R; Dos Anjos, Vanessa; Garcia-Rendueles, Maria E R et al. (2018) Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers. Cancer Res 78:4642-4657
Knauf, Jeffrey A; Luckett, Kathleen A; Chen, Kuen-Yuan et al. (2018) Hgf/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers. J Clin Invest 128:4086-4097
Anelli, Viviana; Villefranc, Jacques A; Chhangawala, Sagar et al. (2017) Oncogenic BRAF disrupts thyroid morphogenesis and function via twist expression. Elife 6:
Tuttle, R Michael; Fagin, James A; Minkowitz, Gerald et al. (2017) Natural History and Tumor Volume Kinetics of Papillary Thyroid Cancers During Active Surveillance. JAMA Otolaryngol Head Neck Surg 143:1015-1020
Xu, Bin; Tuttle, R Michael; Sabra, Mona M et al. (2017) Primary Thyroid Carcinoma with Low-Risk Histology and Distant Metastases: Clinicopathologic and Molecular Characteristics. Thyroid 27:632-640
Montero-Conde, Cristina; Leandro-Garcia, Luis J; Chen, Xu et al. (2017) Transposon mutagenesis identifies chromatin modifiers cooperating with Ras in thyroid tumorigenesis and detects ATXN7 as a cancer gene. Proc Natl Acad Sci U S A 114:E4951-E4960

Showing the most recent 10 out of 53 publications